CorVel Corporation Expands Care Advocacy Program

CorVel Corporation (NASDAQ: CRVL), a national provider of risk management solutions, has redesigned the Care Advocacy model by expanding the important role played by nurses in the first 30 days of a claim.

CorVel Corporation notes the change allows for a personal and customized program for the company’s customers and their employees.

Care Advocacy is the secondary nursing engagement in CorVel’s workers’ compensation program, following the Advocacy 24/7 nurse. This approach leverages CorVel’s integrated CareMC EdgeSM platform, which identifies claims involving moderate to severe worker injuries and connects a nurse care advocate within 24 hours of the first report.

Unlike other early intervention programs, CorVel’s Care Advocacy model involves the nurse as a patient advocate for up to 30 days after initial contact. The Care Advocate educates the injured worker on their medical diagnosis, treatment plan, and return-to-work options, and engages them in the care and recovery process as an active participant. The Care Advocate understands the claim process and ensures the worker receives care and treatment quickly and effectively. This patient-centered approach to claims management empowers the injured worker, resulting in increased satisfaction and timely return to work.

“Our newly expanded Care Advocacy program is implemented during the first 30 days of a claim—a critical time frame that sets the tone for the claim direction and ultimate outcome,” said Karen Thomas, Director of Case Management Innovation at CorVel Corporation. “During that time, our Care Advocates focus on what’s most important: the injured worker and their well-being. They are true patient advocates who help injured workers navigate the often-confusing claim process. This personalized service can improve medical outcomes and reduce the length of a claim.”

The Care Advocates also drive open communication with all claim stakeholders. They provide critical information for the claim specialist in real time using CorVel’s proprietary CareMC EdgeSM platform, which identifies potential challenges before they become issues. As a result, CorVel’s customers have seen an average 49% decrease in litigated claims, 53% decrease in total temporary disability (TTD) payments, and 74% decrease in total medical paid.

“We are very proud of our reimagined Care Advocacy program, which places an emphasis on the injured worker,” said Michael Combs, President and CEO at CorVel. “At CorVel, we believe that a patient-centered approach to claims management supported by collaborative care, innovative technology and an integrated platform can proactively address potential claims challenges. This will improve outcomes and reduce costs for customers while increasing satisfaction and care for injured workers.”

The Care Advocacy program is a key component of CorVel’s comprehensive workers’ compensation program and can be tailored to fit the needs of customers.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”